CCWM
SMMT icon

Cassaday & Co Wealth Management’s Summit Therapeutics SMMT Stock Holding History

Cassaday & Co Wealth Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2
Closed -$38 – 1422
2026
Q1 		$38 Buy
+2
New +$32 ﹤0.01% 1351

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Cassaday & Co Wealth Management's SMMT Position: Q2 2026 in Review

Cassaday & Co Wealth Management sold out of Summit Therapeutics (SMMT) in Q2 2026, closing a stake of 2 shares — an estimated $38 sold.

Cassaday & Co Wealth Management first reported a position in SMMT in Q1 2026 and held it in 1 quarter. The position peaked at $38 in Q1 2026. 243 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Cassaday & Co Wealth Management reported no remaining Summit Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Cassaday & Co Wealth Management sold 2 Summit Therapeutics shares in Q2 2026, an estimated $38.
  • Cassaday & Co Wealth Management first reported a position in Summit Therapeutics in Q1 2026 and held it in 1 quarter.
  • Cassaday & Co Wealth Management's Summit Therapeutics position peaked at $38 in Q1 2026.
  • 243 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Cassaday & Co Wealth Management's 13F filing for Q2 2026, filed 10 Aug 2026.